SCHEMBL4524699

SCHEMBL4524699

COC(=O)C(=O)c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.49
▸ CA2 P00918 3/20 0.49
▸ CA12 O43570 2/20 0.49
▸ CA9 Q16790 2/20 0.49
▸ CA14 Q9ULX7 2/20 0.49
▸ ELANE P08246 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ STAT3 P40763 2/20 0.41
▸ ABCG2 Q9UNQ0 1/20 0.41
▸ GABRA1 P14867 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7346788 0.84 CA1 (0.59) CA1CA2CA12CA9CA14
SCHEMBL109451 0.84 CA1 (0.61) CA1CA2CA12CA9CA14
SCHEMBL2440560 0.82 CA1 (0.61) CA1CA2CA12CA9CA14
SCHEMBL4515841 0.81 CA12 (0.51) CA1CA2CA12CA9CA14
Hydrazine SCHEMBL10771056 0.80 CA12 (0.62) CA1CA2CA12CA9CA14
SCHEMBL10920704 0.80 CYP17A1 (0.52) CA1CA12CA9ALDH1A1
SCHEMBL6350965 0.78 CA12 (0.71) CA1CA2CA12CA9CA14
SCHEMBL4532351 0.78 ELANE (0.60) CA1CA2CA12CA9CA14
SCHEMBL29245017 0.78 CES2 (0.48) CA1CA2ELANETDP1CES2
SCHEMBL11064798 0.77 ELANE (0.67) CA1CA2CA12CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062297-A1 Hydroxyalkylarylamide Derivatives MERCK SHARP & DOHME CORP. 2009-03-05 — — US disclosed
US-20090062297-A1 Hydroxyalkylarylamide Derivatives MERCK SHARP & DOHME CORP. 2009-03-05 — — US disclosed
US-20090062297-A1 Hydroxyalkylarylamide Derivatives MERCK SHARP & DOHME CORP. 2009-03-05 — — US disclosed
EP-1973405-A2 HYDROXYALKYLARYLAMIDE DERIVATIVES Merck & Co., Inc. (US) 2008-10-01 — — EP disclosed
WO-2007087130-A2 HYDROXYALKYLARYLAMIDE DERIVATIVES MERCK & CO., INC. (US) 2007-08-02 — — WO disclosed
WO-2007087130-A2 HYDROXYALKYLARYLAMIDE DERIVATIVES MERCK & CO., INC. (US) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062297-A1 Hydroxyalkylarylamide Derivatives AADAC, HDAC5, HDAC3 CA1 963/4885CA2 1202/4885CA12 2728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback